Navigation Links
Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/15/2009

SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI's pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida.

Ruth Pettengell, M.D. of St. George's Hospital, University of London, an investigator on the study, is scheduled to present the data on Monday, June 1, 2009 during the Lymphoma and Plasma Cell Disorders session that will be held from 2:00 PM-6:00 PM Eastern Time. The presentation, abstract #8523, is titled, "Randomized Phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma." The abstract is available at www.asco.org.

CTI expects to complete the submission of a New Drug Application ("NDA") for pixantrone this quarter and will request priority review which if granted could lead to an approval decision from the U.S. Food and Drug Administration ("FDA") during the fourth quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to r
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
2. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
3. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
9. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... The Thompson Group of Companies announced today that ... a Hamilton Sundstrand Corporation business. AIT will be organized ... terms of the purchase were not disclosed. ... marketing of process analytical instruments including Analect FTIR, PIONIR ...
... Healthcare Diagnostics announces two new three-year agreements with Novation ... chemistry and microscopy systems, and for microbiology systems and ... VHA and University HealthSystem Consortium (UHC) member organizations and ... The members served by Novation have access to ...
Cached Medicine Technology:Thompson Group Acquires Hamilton Sundstrand's Applied Instrument Technologies 2Novation® Awards Siemens as Single Source for Urine Chemistry and Microbiology Systems and Tests 2
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... West Palm Beach, FL (PRWEB) July 12, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
(Date:7/12/2014)... doesn't matter what your budget is, the trendy wedding gowns ... gown can visit Discount-Dress.com (a reliable online store ... Recently, the company has announced its new selection of ... is also providing great discounts for these unique items. All ... promotion is July 29, 2014. , Discount-Dress.com is a ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 Recently, DressyQuinceanera.com, ... 200 Quinceanera Dama dresses to its online ... items are offered at deeply discounted rates, up to ... from DressyQuinceanera.com are equally excellent in terms of quality ... carefully handmade. Similar discounts are also offered for the ...
Breaking Medicine News(10 mins):Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... of Pennsylvania School of Medicine have found an ... kidney transplants and complications during the first week ... MD, PhD, Professor of Pathology and Laboratory Medicine ... Laboratory, and Harold Feldman MD, MSCE, Professor of ...
... SAN DIEGO, Nov. 25 Gen-Probe Incorporated,(Nasdaq: GPRO ... 20th,Annual Piper Jaffray Health Care Conference on Tuesday, December 2, ... webcast live and may be,accessed through a link on the ... will be available for 30 days following,the event. , ...
... but women lagging behind men, study finds , , TUESDAY, Nov. ... allocation system that gives preference to patients with the greatest ... disparities among those waiting for new livers are narrowing. , ... become too sick for a transplant while on the waiting ...
... Nationwide Health Properties, Inc. (NYSE: NHP ) is ... nursing home property company that may be in default on ... similarity of the names, it wanted to clarify that the ... Nationwide Health Properties, Inc. is a real estate ...
... The Pharmacy Technician Certification Board,s (PTCB) Executive Director and CEO, ... Leadership Award, the highest annual honor given by the National ... Corrigan,s innovative leadership in developing, implementing, and researching programs or ... ...
... Citizens Republic Bancorp has,selected HealthPlus Insurance Company to become ... effective January 1, 2009. , ... Wisconsin, and Iowa, will be offered an array of PPO ... "HealthPlus is an outstanding provider of health insurance which like,Citizens, ...
Cached Medicine News:Health News:Understanding donor-recipient genetics could decrease early kidney transplant complications 2Health News:Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference 2Health News:New System Improves Distribution of Donated Livers 2Health News:New System Improves Distribution of Donated Livers 3Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 2Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 3Health News:Citizens Republic Bancorp Selects HealthPlus as Sole Provider of Health Insurance for 2009 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: